Abstract
Background: This study's purposes were to characterize detection rates of several sexually transmitted infection (STI) agents and describe the effect additional specimen source and analyte screening has on STI detectionwithin a cohort of young men who have sex with men and transgender women. Methods:Within a 16-month interval, 1966 encounters involved dual urine and rectal swab submissions assessed by commercial transcription-mediated amplification-based assays for Chlamydia trachomatis and Neisseria gonorrhoeae and by off-label transcription-mediated amplification-based Trichomonas vaginalis and Mycoplasma genitalium testing. Identification of STI carriers used algorithms involving Food and Drug Administration- cleared screening methods, laboratory-modified testing for extraurogenital C. trachomatis and N. gonorrhoeae, and laboratory-developed tests for T. vaginalis and M. genitalium. Results: Food and Drug Administration-indicated urine C. trachomatis and N. gonorrhoeae screening revealed 39 encounters (2.0%) yielding one or both agents. Via C. trachomatis and N. gonorrhoeae screening that included rectal swab analysis, 264 encounters (13.4%) yielded evidence of either (140 C. trachomatis, 88 N. gonorrhoeae) or both (36 participants) infections. Detection rates for C. trachomatis and N. gonorrhoeae were 1.4% and 0.6% for urine screening and 8.2% and 6.2% for rectal screening, respectively. Off-label screening identified 413 additional encounters with STI (5 T. vaginalis, 396 M. genitalium, 12 with both). Of these identifications, 82.1% were generated from analysis of rectal swabs (4 participants with T. vaginalis, 323 participants with M. genitalium, 12 with both). Overall detection rates of T. vaginalis (0.2% urine, 1.3%rectal) and M. genitalium (9.1% urine, 21.5% rectal) were variable. Conclusions: Additive analyte testing, including extraurogenital collections, contributes to comprehensive STI screening within a high-risk demographic.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 748-753 |
| Number of pages | 6 |
| Journal | Sexually Transmitted Diseases |
| Volume | 47 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2020 |
Funding
Background: This study's purposes were to characterize detection rates of several sexually transmitted infection (STI) agents and describe the effect additional specimen source and analyte screening has on STI detection within a cohort of young men who have sex with men and transgender women. Methods: Within a 16-month interval, 1966 encounters involved dual urine and rectal swab submissions assessed by commercial transcription-mediated amplification–based assays for Chlamydia trachomatis and Neisseria gonorrhoeae and by off-label transcription-mediated amplification–based Trichomonas vaginalis and Mycoplasma genitalium testing. Identification of STI carriers used algorithms involving Food and Drug Administration– cleared screening methods, laboratory-modified testing for extraurogenital C. trachomatis and N. gonorrhoeae, and laboratory-developed tests for T. vaginalis and M. genitalium. Results: Food and Drug Administration–indicated urine C. trachomatis and N. gonorrhoeae screening revealed 39 encounters (2.0%) yielding one or both agents. Via C. trachomatis and N. gonorrhoeae screening that included rectal swab analysis, 264 encounters (13.4%) yielded evidence of either (140 C. trachomatis,88 N. gonorrhoeae) or both (36 participants) infections. Detection rates for C. trachomatis and N. gonorrhoeae were 1.4% and 0.6% for urine screening and 8.2% and 6.2% for rectal screening, respectively. Off-label screening identified 413 additional encounters with STI (5 T. vaginalis, 396 M. genitalium, 12 with both). Of these identifications, 82.1% were generated from analysis of rectal swabs (4 participants From the *College of Health Sciences, Marquette University, Milwaukee, WI; and †Northwestern University Institute for Sexual and Gender Mi-nority Health and Wellbeing, Chicago, IL Acknowledgments: The authors wish to thank Justin Franz, Peter Cleary, and Michael Pulte for assistance at the RADAR study sites and all of the research participants. The RADAR study was supported by grants from the National Institute on Drug Abuse (U01DA036939, principal investigator: B. Mustanski; F32DA046313, principal investigator: E. Morgan). Conflict of Interest and Sources of Funding: E.M. has received honoraria and travel grants from Hologic, Incorporated. B.M. has received consulting fees from Hologic, Incorporated. For the remaining authors, none were declared. This work was funded by grants from the National Institute on Drug Abuse (U01DA036939; F32DA046313). Hologic, Incorporated, provided multitest swab and urine collection kits, as well as testing reagents for the study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health. The sponsor had no involvement in the conduct of the research.
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Microbiology (medical)
- Infectious Diseases
- Dermatology